Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index

Gynecological Endocrinology

Volumn 24, Issue 11, 2008, Pages 620-624

  Chedraui, Peter ^a   San Miguel, Glenda ^a   Hidalgo, Luis ^a   Morocho, Nancy ^a   Ross, Susana ^a  

^a UNIVERSIDAD CATÓLICA DE SANTIAGO DE GUAYAQUIL   (Ecuador)

Author keywords

Cardiovascular risk; Dyslipidemia; Isoflavones; Obesity; Red clover; Trifolium pratense

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOFLAVONE DERIVATIVE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MENOFLAVON; PLACEBO; RED CLOVER EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RED CLOVER; SUPPLEMENTATION; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

BODY MASS INDEX; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; ISOFLAVONES; LIPIDS; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; POSTMENOPAUSE; TRIFOLIUM;

EID: 56749105557     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802288283     Document Type: Article

References (34)

1. Bhavnani BR, Strickler RC. Menopausal hormone therapy. J Obstet Gynaecol Can 2005;27:137-162.
2. Castelo-Branco C, Rostro F. Management of menopause. Minerva Ginecol 2006;58:137-152.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
4. Blumel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gomez MS, Sarra S. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 2004;11:57-61.
5. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.
6. Lazar F Jr, Costa-Paiva L, Morais SS, Pedro AO, Pinto-Neto AM. The attitude of gynecologists in Sao Paulo, Brazil 3 years after the Women's Health Initiative study. Maturitas 2007;56:129-141.
7. Nassar AH, Abd Essamad HM, Awwad JT, Khoury NG, Usta IM. Gynecologists' attitudes towards hormone therapy in the post 'Women's Health Initiative' study era. Maturitas 2005;52:18-25.
8. Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993;44:37-43.
9. Miksicek RJ. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 1994;49:153-160.
10. Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A. Estrogenic activity of two standardized red clover extracts (Menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001;78:67-75.
11. Simoncini T, Fornari L, Mannella P, Caruso A, Garibaldi S, Baldacci C, Genazzani AR. Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. Menopause 2005;12:69-77.
12. Rathel TR, Leikert JF, Vollmar AM, Dirsch VM. The soy isoflavone genistein induces a late but sustained activation of the endothelial nitric oxide-synthase system in vitro.Br J Pharmacol 2005;144:394-399.
13. Imhof M, Gocan A, Reithmayr F, Lipovac M, Schimitzek C, Chedraui P, Huber J. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas 2006;55:76-81.
14. Chedraui P, Hidalgo L, San Miguel G, Morocho N, Ross S. Red clover extract (MF11RCE) supplementation and postmenopausal vaginal and sexual health. Int J Gynaecol Obstet 2006;95:296-297.
15. Hidalgo LA, Chedraui PA, Morocho N, Ross S, San Miguel G. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol Endocrinol 2005;21:257-264.
16. Samman S, Lyons Wall PM, Chan GS, Smith SJ, Petocz P. The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in premenopausal women. Atherosclerosis 1999;147:277-283.
17. Atkinson C, Oosthuizen W, Scollen S, Loktionov A, Day NE, Bingham SA. Modest protective effects of isoflavones from a red clover-derived dietary supplement on cardiovascular disease risk factors in perimenopausal women, and evidence of an interaction with ApoE genotype in 49-65 year-old women. J Nutr 2004;134:1759-1764.
18. Nestel P, Cehun M, Chronopoulos A, DaSilva L, Teede H, McGrath B. A biochanin-enriched isoflavone from red clover lowers LDL cholesterol in men. Eur J Clin Nutr 2004;58:403-408.
19. Howes JB, Sullivan D, Lai N, Nestel P, Pomeroy S, West L, Eden JA, Howes RG. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis 2000;152:143-147.
20. Blakesmith SJ, Lyons-Wall PM, George C, Joannou GE, Petocz P, Samman S. Effects of supplementation with purified red clover (Trifolium pratense) isoflavones on plasma lipids and insulin resistance in healthy premenopausal women. Br J Nutr 2003;89:467-474.
21. Hidalgo LA, Chedraui PA, Morocho N, Alvarado M, Chavez D, Huc A. The metabolic syndrome among postmenopausal women in Ecuador. Gynecol Endocrinol 2006;22:447-454.
22. Royer M, Castelo-Branco C, Blumel JE, Chedraui PA, Danckers L, Bencosme A, Navarro D, Vallejo S, Espinoza MT, Gómez G. et al.; Collaborative Group for Research of the Climacteric in Latin America. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 2007;10:164-170.
23. Alexander J, Clearfield M. Cardiovascular disease after menopause: a growing epidemic. Minerva Ginecol 2006;58:35-40.
24. Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Quality of life among postmenopausal Ecuadorian women participating in a metabolic syndrome screening program. Maturitas 2007;56:45-53.
25. Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. Arch Gynecol Obstet 2007;275:161-168.
26. Wang MF, Yamamoto S, Chung HM, Chung SY, Miyatani S, Mori M, Okita T, Sugano M. Antihypercholesterolemic effect of undigested fraction of soybean protein in young female volunteers. J Nutr Sci Vitaminol (Tokyo) 1995;41:187-195.
27. Schult TM, Ensrud KE, Blackwell T, Ettinger B, Wallace R, Tice JA. Effect of isoflavones on lipids and bone turnover markers in menopausal women. Maturitas 2004;48:209-218.
28. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001;8:259-265.
29. Cancellieri F, De Leo V, Genazzani AD, Nappi C, Parenti GL, Polatti F, Ragni N, Savoca S, Teglio L, Finelli F, et al. Efficacy on menopausal neurovegetative symptoms and some plasma lipids blood levels of an herbal product containing isoflavones and other plant extracts. Maturitas 2007;56:249-256.
30. Allen JK, Becker DM, Kwiterovich PO, Lindenstruth KA, Curtis C. Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. Menopause 2007;14:106-114.
31. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 2007;58:249-258.
32. Aubertin-Leheudre M, Lord C, Khalil A, Dionne IJ. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study. Menopause 2007;14:624-629.
33. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G,Woodward M, Rumley A, Lowe GD, Danesh J, Gudnason V. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008;168:598-608.
34. Shai I, Schulze MB, Manson JE, Stampfer MJ, Rifai N, Hu FB. A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes. Diabetologia 2005;48:1469-1476.